Survival outcomes of adjuvant chemotherapy with modified weekly nab-paclitaxel and carboplatin for completely resected nonsmall cell lung cancer: FAST-nab

The relatively low toxicity profile of nab-paclitaxel plus carboplatin and its feasibility as an adjuvant administration was reported previously. This study aimed to evaluate the survival efficacy for completely resected patients with stage IB, II, and IIIA nonsmall cell lung cancer (NSCLC). Twenty-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Anticancer Drugs
Main Authors: Marushima, Hideki, Kimura, Hiroyuki, Miyazawa, Tomoyuki, Sakai, Hiroki, Furuya, Naoki, Koji, Kojima, Nakamura, Haruhiko, Saji, Hisashi
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2020
Assuntos:
Clinical Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6964868/
https://ncbi.nlm.nih.gov/pubmed/31725045
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CAD.0000000000000857
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados